Literature DB >> 33185461

Oxidation of Protein Kinase A Regulatory Subunit PKARIα Protects Against Myocardial Ischemia-Reperfusion Injury by Inhibiting Lysosomal-Triggered Calcium Release.

Jillian N Simon1, Besarte Vrellaku1, Stefania Monterisi2, Sandy M Chu1, Nadiia Rawlings1, Oliver Lomas1, Gerard A Marchal1, Dominic Waithe3, Fahima Syeda4, Parag R Gajendragadkar1, Raja Jayaram1, Rana Sayeed5, Keith M Channon1, Larissa Fabritz4,6, Pawel Swietach2, Manuela Zaccolo2, Philip Eaton7, Barbara Casadei1.   

Abstract

BACKGROUND: Kinase oxidation is a critical signaling mechanism through which changes in the intracellular redox state alter cardiac function. In the myocardium, PKARIα (type-1 protein kinase A) can be reversibly oxidized, forming interprotein disulfide bonds in the holoenzyme complex. However, the effect of PKARIα disulfide formation on downstream signaling in the heart, particularly under states of oxidative stress such as ischemia and reperfusion (I/R), remains unexplored.
METHODS: Atrial tissue obtained from patients before and after cardiopulmonary bypass and reperfusion and left ventricular (LV) tissue from mice subjected to I/R or sham surgery were used to assess PKARIα disulfide formation by immunoblot. To determine the effect of disulfide formation on PKARIα catalytic activity and subcellular localization, live-cell fluorescence imaging and stimulated emission depletion super-resolution microscopy were performed in prkar1 knock-out mouse embryonic fibroblasts, neonatal myocytes, or adult LV myocytes isolated from "redox dead" (Cys17Ser) PKARIα knock-in mice and their wild-type littermates. Comparison of intracellular calcium dynamics between genotypes was assessed in fura2-loaded LV myocytes, whereas I/R-injury was assessed ex vivo.
RESULTS: In both humans and mice, myocardial PKARIα disulfide formation was found to be significantly increased (2-fold in humans, P=0.023; 2.4-fold in mice, P<0.001) in response to I/R in vivo. In mouse LV cardiomyocytes, disulfide-containing PKARIα was not found to impact catalytic activity, but instead led to enhanced AKAP (A-kinase anchoring protein) binding with preferential localization of the holoenzyme to the lysosome. Redox-dependent regulation of lysosomal two-pore channels by PKARIα was sufficient to prevent global calcium release from the sarcoplasmic reticulum in LV myocytes, without affecting intrinsic ryanodine receptor leak or phosphorylation. Absence of I/R-induced PKARIα disulfide formation in "redox dead" knock-in mouse hearts resulted in larger infarcts (2-fold, P<0.001) and a concomitant reduction in LV contractile recovery (1.6-fold, P<0.001), which was prevented by administering the lysosomal two-pore channel inhibitor Ned-19 at the time of reperfusion.
CONCLUSIONS: Disulfide modification targets PKARIα to the lysosome, where it acts as a gatekeeper for two-pore channel-mediated triggering of global calcium release. In the postischemic heart, this regulatory mechanism is critical for protection from extensive injury and offers a novel target for the design of cardioprotective therapeutics.

Entities:  

Keywords:  calcium signaling; lysosome; protein kinase A phosphorylation; redox; reperfusion injury

Mesh:

Substances:

Year:  2020        PMID: 33185461      PMCID: PMC7846288          DOI: 10.1161/CIRCULATIONAHA.120.046761

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  56 in total

1.  Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor.

Authors:  Cathrine Rein Carlson; Birgitte Lygren; Torunn Berge; Naoto Hoshi; Wei Wong; Kjetil Taskén; John D Scott
Journal:  J Biol Chem       Date:  2006-05-25       Impact factor: 5.157

2.  Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism.

Authors:  R A Forbes; C Steenbergen; E Murphy
Journal:  Circ Res       Date:  2001-04-27       Impact factor: 17.367

3.  Prostaglandin E1 activation of heart cAMP-dependent protein kinase: apparent dissociation of protein kinase activation from increases in phosphorylase activity and contractile force.

Authors:  S L Keely
Journal:  Mol Pharmacol       Date:  1979-03       Impact factor: 4.436

4.  Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins.

Authors:  Kiran S Nadella; Lawrence S Kirschner
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  Mitochondria-lysosome contacts regulate mitochondrial Ca2+ dynamics via lysosomal TRPML1.

Authors:  Wesley Peng; Yvette C Wong; Dimitri Krainc
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-23       Impact factor: 11.205

Review 6.  NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury.

Authors:  Pamela W M Kleikers; K Wingler; J J R Hermans; I Diebold; S Altenhöfer; K A Radermacher; B Janssen; A Görlach; H H H W Schmidt
Journal:  J Mol Med (Berl)       Date:  2012-10-23       Impact factor: 4.599

Review 7.  ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection.

Authors:  Susana Cadenas
Journal:  Free Radic Biol Med       Date:  2018-01-31       Impact factor: 7.376

8.  Structure of D-AKAP2:PKA RI complex: insights into AKAP specificity and selectivity.

Authors:  Ganapathy N Sarma; Francis S Kinderman; Choel Kim; Sventja von Daake; Lirong Chen; Bi-Cheng Wang; Susan S Taylor
Journal:  Structure       Date:  2010-02-10       Impact factor: 5.006

9.  Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore.

Authors:  Sean M Davidson; Kirsty Foote; Suma Kunuthur; Raj Gosain; Noah Tan; Richard Tyser; Yong Juan Zhao; Richard Graeff; A Ganesan; Michael R Duchen; Sandip Patel; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2015-09-22       Impact factor: 10.787

10.  High resolution structural evidence suggests the Sarcoplasmic Reticulum forms microdomains with Acidic Stores (lysosomes) in the heart.

Authors:  Daniel Aston; Rebecca A Capel; Kerrie L Ford; Helen C Christian; Gary R Mirams; Eva A Rog-Zielinska; Peter Kohl; Antony Galione; Rebecca A B Burton; Derek A Terrar
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

View more
  6 in total

Review 1.  Regulation of Cardiac PKA Signaling by cAMP and Oxidants.

Authors:  Friederike Cuello; Friedrich W Herberg; Konstantina Stathopoulou; Philipp Henning; Simon Diering
Journal:  Antioxidants (Basel)       Date:  2021-04-24

2.  SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardial Ischemia/Reperfusion Injury.

Authors:  Dawei Wang; Hongyan Cao; Xu Wang; Jinchun Wang; Manli Wang; Jian Zhang; Lin Wang
Journal:  J Inflamm Res       Date:  2021-04-07

3.  Verapamil Alleviates Myocardial Ischemia/Reperfusion Injury by Attenuating Oxidative Stress via Activation of SIRT1.

Authors:  Mi Bao; Weiyi Huang; Yang Zhao; Xinzhe Fang; Yanmei Zhang; Fenfei Gao; Danmei Huang; Bin Wang; Ganggang Shi
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

4.  Two-pore channels: going with the flows.

Authors:  Anthony J Morgan; Lora L Martucci; Lianne C Davis; Antony Galione
Journal:  Biochem Soc Trans       Date:  2022-08-31       Impact factor: 4.919

5.  Enhanced Heart Failure in Redox-Dead Cys17Ser PKARIα Knock-In Mice.

Authors:  M M Towhidul Islam; Daniel Tarnowski; Min Zhang; Maximilian Trum; Simon Lebek; Julian Mustroph; Henriette Daniel; Johanna Moellencamp; Steffen Pabel; Samuel Sossalla; Ali El-Armouche; Viacheslav O Nikolaev; Ajay M Shah; Philip Eaton; Lars S Maier; Can Martin Sag; Stefan Wagner
Journal:  J Am Heart Assoc       Date:  2021-09-29       Impact factor: 5.501

6.  A Selective Inhibitor of Cardiac Troponin I Phosphorylation by Delta Protein Kinase C (δPKC) as a Treatment for Ischemia-Reperfusion Injury.

Authors:  Nir Qvit; Amanda J Lin; Aly Elezaby; Nicolai P Ostberg; Juliane C Campos; Julio C B Ferreira; Daria Mochly-Rosen
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.